Kupffer cells in non-alcoholic fatty liver disease: The emerging view

被引:362
|
作者
Baffy, Gyoergy [1 ,2 ]
机构
[1] Harvard Univ, Sch Med, Brigham & Womens Hosp, Gastroenterol Sect, Boston, MA 02130 USA
[2] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Gastroenterol Sect, Boston, MA 02130 USA
关键词
Steatohepatitis; Macrophages; Toll-like receptors; Adiponectin; Uncoupling protein; TNF-ALPHA PRODUCTION; TOLL-LIKE RECEPTORS; UNCOUPLING PROTEIN-2; INSULIN-RESISTANCE; SCAVENGER RECEPTOR; NADPH OXIDASE; ISCHEMIA/REPERFUSION INJURY; ALTERNATIVE ACTIVATION; ADIPONECTIN RECEPTORS; MOLECULAR-MECHANISMS;
D O I
10.1016/j.jhep.2009.03.008
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Non-alcoholic fatty liver disease (NAFLD) has become the most common liver disorder of our times. Simple steatosis, a seemingly innocent manifestation of NAFLD, may progress into steatohepatitis and cirrhosis, but this process is not well understood. Since NAFLD is associated with obesity and insulin resistance, mechanisms that link lipid metabolism to inflammation offer insights into the pathogenesis. An important parallel between obesity-related pathology of adipose tissue and liver pertains to the emerging role of macrophages and evidence is growing that Kupffer cells critically contribute to progression of NAFLD. Toll-like receptors, in particular TLR4, represent a major conduit for danger recognition linked to Kupffer cell activation and this process may be perturbed at multiple steps in NAFLD. Steatosis may interfere with sinusoid microcirculation and hepatocellular clearance of microbial and host-derived danger signals, enhancing responsiveness of Kupffer cells. Altered lipid homeostasis in NAFLD may unfavourably affect TLR4 receptor complex assembly and sorting, interfere with signalling flux redistribution, promote amplification loops, and impair negative regulation including alternative activation of Kupffer cells. These events are further promoted by altered adipokine secretion and reactive oxygen species production. Specific targeting of these interactions may provide more effective strategies in the treatment of NAFLD. Published by Elsevier B.V. on behalf of the European Association for the Study of the Liver.
引用
收藏
页码:212 / 223
页数:12
相关论文
共 50 条
  • [1] Kupffer Cells in Non-alcoholic Fatty Liver Disease: Friend or Foe?
    Chen, Jiajia
    Deng, Xiaoyi
    Liu, Yongjian
    Tan, Qiuhua
    Huang, Guidong
    Che, Qishi
    Guo, Jiao
    Su, Zhengquan
    [J]. INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2020, 16 (13): : 2367 - 2378
  • [2] Targeting Kupffer cells in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why and how?
    Nicolas Lanthier
    [J]. World Journal of Hepatology, 2015, (19) : 2184 - 2188
  • [3] Targeting Kupffer cells in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why and how?
    Lanthier, Nicolas
    [J]. WORLD JOURNAL OF HEPATOLOGY, 2015, 7 (19) : 2184 - 2188
  • [4] Emerging drugs for non-alcoholic fatty liver disease
    Federico, Alessandro
    Niosi, Marco
    Blanco, Camillo Del Vecchio
    Loguercio, Carmela
    [J]. EXPERT OPINION ON EMERGING DRUGS, 2008, 13 (01) : 145 - 158
  • [5] Non-alcoholic fatty liver disease: An emerging liver disease in Taiwan
    Hsu, Ching-Sheng
    Kao, Jia-Horng
    [J]. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2012, 111 (10) : 527 - 535
  • [6] Study on the phenotype changes of kupffer cells in non-alcoholic fatty liver
    Li, Yang
    Jiang, Haitao
    Xian, Jianchun
    Zhang, Wei
    Xiao, Li
    Gan, Jianhe
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (10): : 19027 - 19033
  • [7] Chitotriosidase gene expression in Kupffer cells from patients with non-alcoholic fatty liver disease
    Malaguarnera, L.
    Di Rosa, M.
    Zambito, A. M.
    dell'Ombra, N.
    Nicoletti, F.
    Malaguarnera, M.
    [J]. GUT, 2006, 55 (09) : 1313 - 1320
  • [8] Emerging Diagnostics and Therapeutics for Non-alcoholic Fatty Liver Disease
    Darbhanga, Jake
    Krulikowski, Kiarra
    Riskin, Suzanne I.
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (10)
  • [9] Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease
    Patel, Samarth Siddharth
    Siddiqui, Mohammad Shadab
    [J]. DRUGS, 2019, 79 (01) : 75 - 84
  • [10] Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease
    Samarth Siddharth Patel
    Mohammad Shadab Siddiqui
    [J]. Drugs, 2019, 79 : 75 - 84